Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers, a recent study published online ahead of print in the journal The Lancet Haematology has shown.
Previous research has demonstrated that patients with chronic myeloproliferative neoplasms, such as chronic myelogenous leukemia (CML) and primary myelofibrosis, are at an increased risk for developing new hematological or solid cancers.
Researchers sought to evaluate how preceding myeloproliferative neoplasms impact the prognosis of patients who develop a new primary cancer.
For the study, researchers analyzed data from 1,246 patients with a history of myeloproliferative neoplasms from population-based databases in Denmark from 1980 to 2011. Patients were compared to 5,155 subjects without a history of myeloproliferative neoplasm.
Results showed that among those with new localized solid tumors, the 5-year survival was 49.8% (95% CI: 39.1, 59.6), 47.9% (95% CI: 42.1, 53.4), and 48.0% (95% CI: 34.1, 60.7) for patients with preceding essential thrombocythemia, polycythemia vera, and chronic myeloid leukemia, respectively.
RELATED: Imatinib Safe, Effective in Treatment of Chronic Myeloid Leukemia
In matched patients without preceding myeloproliferative neoplasms, the 5-year survival rates were 72.4% (95% CI: 68.4, 76.0), 63.9% (95% CI: 61.5, 66.2), and 74.3% (95% CI: 68.2, 79.4), respectively.
Researchers found that patients with a preceding myeloproliferative neoplasm and a new solid tumor had a 1.21 to 2.28 times higher risk of death compared with those without myeloproliferative neoplasms.